J&J Gains Successor to Zytiga® with Aragon Pharmaceuticals Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 7 (Table of Contents)
Published: 3 Jul-2013
DOI: 10.3833/pdr.v2013.i7.1959 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to extend its prostate cancer franchise, Johnson & Johnson (J&J) has agreed to acquire Aragon Pharmaceuticals in a deal worth up to US$1 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS